Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications
| Autor: | Juan Pablo Arab, Felipe Contreras-Briceño, Francisco Barrera, Maximiliano Espinosa-Ramírez, Antonio López-Fuenzalida, Tiziana Fernández-Mincone, Daniel Cabrera, Marco Arrese, Patricio García-Valdés, Arnoldo Riquelme |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Sarcopenia
Hepatology business.industry Gastroenterology Skeletal muscle medicine.disease Skeletal muscle mass Bioinformatics Pathophysiology 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Non-alcoholic Fatty Liver Disease 030220 oncology & carcinogenesis Nonalcoholic fatty liver disease Disease Progression medicine Humans 030211 gastroenterology & hepatology Steatohepatitis Steatosis Muscle Skeletal business |
| Zdroj: | Expert Review of Gastroenterology & Hepatology. 14:1141-1157 |
| ISSN: | 1747-4132 1747-4124 |
| Popis: | Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common liver diseases worldwide. Recent data suggest that loss of skeletal muscle mass and function (i.e. sarcopenia) is highly prevalent and frequently overlooked in NAFLD patients. Experimental and clinical data suggest that the relationship between NAFLD and sarcopenia is pathophysiologically complex and bi-directional and there is a growing interest in unveiling how sarcopenia could influence NAFLD development and progression.PubMed/MEDLINE was searched for articles related to concomitant occurrence of NAFLD and sarcopenia between January 2013 and April 2020. Areas covered in this review include: (1) updated sarcopenia diagnosis strategy, (2) discussion of current data on pathophysiological connections between NAFLD and sarcopenia, and (3) analysis of current and future therapeutic implications of this knowledge.Clinical studies describe a consistent association between NAFLD and sarcopenia, although a cause-effect relation remains to be determined. Active implementation of current diagnosis algorithms and optimized treatment can prevent sarcopenia related complications in subjects with NAFLD. Pathogenic pathways implicated in this relation are multiple and complex, a better understanding of them can provide novel biomarkers and targeted therapies that will hopefully have an important impact in NAFLD management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|